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CC BY-NC-ND license (http://creativBackground: There are limited data about the results of repeated oral ibuprofen (OIBU) treat-
ment. This study aimed to describe patent ductus arteriosus (PDA) closure rates and adverse
events after repeated courses of OIBU in premature infants with PDA.
Methods: Preterm infants with hemodynamically significant (hs)PDA were enrolled in the
study. If the first course of OIBU treatment failed, a second and, if required, third course
was administered.
Results: A total of 100 patients received OIBU. In six patients, treatment could not be
completed due to death (nZ 3) and side effects (nZ 3). In three patients, adverse effects
related to OIBU (thrombocytopenia and impairment of renal function) developed during the
first course. During the second and third courses, no new adverse event occurred. After all
courses, the PDA closure rate was determined as 88%. The rate was 71% after the first course,
40% after the second course, and 35% after the third course. Although the second course re-
sulted in a significant increase in the closure rate (p< 0.05), the rate did not increase signif-
icantly with the third course (p> 0.05). The mean postnatal age at the start of the first dose of
OIBU was not significantly different among the responders and non-responders to the first
course (p> 0.05). Clinical characteristics did not affect the closure rate significantly. The num-
ber of courses did not have a significant effect on death, when gestational age and birth weight
were used as covariates [pZ 0.867, Exp(B)Z 0.901, 95% confidence intervalZ 0.264e3.1].
Conclusion: A second course of OIBU seems effective and safe for use in preterm infants with
hsPDA. Although a third course of OIBU results in PDA closure in some additional patients, theversity School of Medicine, Division of Pediatric Cardiology, 25240, Erzurum, Turkey.
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Efficacy and Safety, Pediatrics and Ndifference is not significant. Thus, surgical ligation should be considered after the second
course, especially in patients with signs of severe heart failure.
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Hemodynamically significant patent ductus arteriosus
(hsPDA) is one of the most common problems in premature
infants. Many studies have shown that cyclooxygenase
(COX) inhibitors [indomethacin, ibuprofen (IBU)]1e3 and
surgical closure4 are effective in closing the ductus arte-
riosus in premature infants. However, the debate is ongoing
about the selection of the treatment method, and there is
still no consensus about the benefiteside effect relation.
Because of the reported association of surgical ligation with
an increased risk of chronic lung disease, retinopathy of
prematurity, and neurodevelopmental impairment
compared to indomethacin therapy,4,5 repeated courses of
COX inhibitors are being tried. Although there are previ-
ously published data on the efficacy of repeated courses of
indomethacin,6,7 the data available regarding repeated
courses of intravenous (IV) IBU are limited.8,9 Repeated
courses of IV IBU are reported to be effective for closure,
with a low complication rate.9 To the best of our knowl-
edge, there is no report in the current literature on the
effect of repeated courses of oral ibuprofen (OIBU) on the
ductal closure rate. In the present study, we aimed to
evaluate the PDA closure rates and frequency of compli-
cations related to IBU after single and multiple courses of
OIBU in a population of premature infants with hsPDA.2. Methods
The medical records of preterm infants who had been fol-
lowed in a single-center tertiary neonatal unit from 2008 to
2010were evaluated retrospectively. Clinical features of 100
pretermbabieswith hsPDAwhowere treatedwithOIBUwere
analyzed. Gestational age (GA), birth weight (BW), gender, 5
minute Apgar score, antenatal steroid usage, age at first IBU
administration, vasopressor (dopamine, dobutamine) use,
and echocardiographic findings were recorded. Institutional
Review Board approval (Ethics committee of Ataturk Uni-
versity Medical Studies Department, Erzurum) was obtained
for the study. For diagnosis and follow-up, echocardiography
and Doppler ultrasonography were used for PDA.
In our unit, preterm babies with clinical signs of PDA (e.g.,
cardiacmurmur, boundingpulses, hyperdynamic precordium,
and/or significant respiratory distress) are evaluated clini-
cally and by echocardiography. If PDA is detected, it is
considered to be hemodynamically significant and to neces-
sitate treatment when the ductus is moderate to large in size
(diameter of ductal area at the narrowest site > 1.5 mm on
color Doppler echocardiography), with evidence of left-to-
right ductal shunting and an increased left atrium to aortic
ratio (> 1.3). The first dose of IBU (10 mg/kg) is administered
vianasogastric tube.Afterwards, twoadditional doses ofOIBUun H, et al., Repeated Courses of
eonatology (2016), http://dx.doiof 5 mg/kg are given at 24-hour intervals (1 course).10 The
patient is assessed clinically and echocardiographically at 24
hours following the third dose. The treatment is accepted to
be successful if clinical signs improve, PDAflowdisappears, or
the ductal shunt is minimal on echocardiography. If hsPDA
persists, a second and, if required, third course of IBU treat-
ment is initiated. Indications for immediate surgical closure
are congestive heart failure and respiratory instability due to
PDA after two courses of OIBU and a persistent PDA with a
significant left-to-right shunt after the third course.
OIBU is not administered in the presence of major
congenital anomalies, Grade 3 intraventricular hemorrhage
according to Papile classification, tendency to hemorrhage,
hyperbilirubinemia requiring blood exchange, and necro-
tizing enterocolitis (NEC) or suspected NEC, or in patients
with serum creatinine > 1.6 mg/dL, blood urea nitrogen
(BUN) > 50 mg/dL, and platelet count < 60,000/mL3. IBU-
administered patients are followed for renal, gastrointes-
tinal, and cerebral side effects. Serum BUN, creatinine,
sodium levels, and platelet counts are evaluated before
and after treatment in each course. During treatment,
elevation in serum creatinine level to > 1.6 mg/dL and
decreases in urine output to < 1 mL/kg/h, serum sodium
level to < 125 mEq/L, and platelet count to < 60,000/mL3
are accepted as side effects of IBU.
2.1. Statistical analysis
Statistical analysis was performed with SPSS for Windows
version 20 (IBM, Armonk, NY, USA). The normality of the dis-
tribution of the quantitative variables was assessed by Sha-
piroeWilk test. Descriptive statistics are shown as
mean standard deviation or median (minimumemaximum)
for constant variables. Nominal variables are defined as
number of cases and percentage. The significance of differ-
ences between groups in terms of mean values was evaluated
with ManneWhitney U test. Nominal variables were analyzed
using Pearson’s Chi-square test or Fisher’s exact test.
Cochran’s Q and McNemar tests were used for evaluation of
the significanceofan increase incumulativeclosure rateswith
an increasing number of courses. Binary logistic regression
analysiswas used to analyze the effect of repeated courses on
death. A p value < 0.05 was accepted as significant.
3. Results
Five hundred and seventy-six preterm babies (gestational
age < 37 weeks) were admitted to the Newborn Intensive
Care Unit of Atatu¨rk University, School of Medicine (Erzu-
rum, Turkey), between March 2008 and May 2010. PDA was
detected in 134 of them. Shunting in 34 (25.3%) of the 134
patients was hemodynamically insignificant and the PDAsOral Ibuprofen in Premature Infants with Patent Ductus Arteriosus:
.org/10.1016/j.pedneo.2015.04.017
Table 2 Clinical features of the cases (nZ 94).
n %
Use of antenatal steroids 36 38.3
Chorioamnionitis 4 4.3
Asphyxia 14 14.9
RDS 67 71.3
Sepsis 56 59.6
Use of inotropic agents 39 41.5
Course No.
1 67 71.3
2 13 13.8
3 14 14.9
IVH 4 4.3
PVL 1 1.1
BPD 31 33
NEC, isolated perforation 8 8.5
Death (mean, d) 24 25.5
ROP 16 17
Length of hospital stay (d, range) 44 (3e126)
BPDZ bronchopulmonary dysplasia; IVHZ intraventricular
hemorrhage; NECZ necrotizing enterocolitis; PDAZ patent
ductus arteriosus; PVLZ periventricular leukomalacia;
RDSZ respiratory distress syndrome; ROPZ retinopathy of
prematurity.
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OIBU treatment was started were included in this study.
Three patients were excluded due to death before
completion of a full course of OIBU. The data of the
remaining 97 patients were evaluated.
Of the 97 patients, 52 (53.6%) were male and 45 (46.4%)
were female infants. Mean GA was 30.6 3.4 weeks (range,
24e36 weeks) and BWwas 1220 480 g (range, 490e3000 g).
Sixty-nine (71.1%) of the patients were very low birth weight
or extremely low birth weight infants. Demographic features
of the patients are given in Table 1 and clinical features in
Table 2. There was only one patient with a length of hospital
stay of 3 days. He was diagnosed as having hsPDA on the
Postnatal Day 3 at a pediatric cardiology outpatient clinic.
The infant was a 35-week infant. Because of the clinical
condition of the patient, we thought that present ductus
should be closed. The patient responded to OIBU. After the
last dose of ibuprofen, PDA was closed and the family dis-
charged the patient without permission of the newborn
team. Follow-up of the patient was done at the outpatient
clinic. No adverse event related to OIBU developed and duct
reopening was not observed at follow-up visits.
3.1. Adverse events
In three patients, IBU was stopped prior to completion of a
whole course of OIBU due to the development of thrombo-
cytopenia (nZ 1), thrombocytopenia and impairment of
renal function (nZ 1), and impairment of renal function
(nZ 1). These were considered as complications of OIBU. All
complications developed during the first course, and when
IBU was ceased, the PDA remained patent. Complications
resolved after discontinuation of the drug. These patients
were not considered in the calculation of closure rates.
3.2. Closure rate
PDAwasclosed in 67 (71%)of 94patients after thefirst course.
No reopening was observed among these patients. A second
course was administered in 27 (29%) patients, and in 11 (40%)Table 1 Demographic features of patients in whom at
least one oral ibuprofen course could be completed.
Variables nZ 97
Sex
Male 50 (53.2)
Female 44 (46.8)
Gestational age (y) 30.6 3.4 (24e36)
Gestational age groups (wk)
< 30 38 (40.4)
30e34 41 (43.6)
> 34 15 (16.0)
Birth weight (g) 1220 480 (490e3000)
Birth weight groups (g)
< 1000 30 (31.9)
1000e1500 37 (39.4)
> 1500 27 (28.7)
Data are presented as n (%) or mean standard deviation
(range).
Please cite this article in press as: Olgun H, et al., Repeated Courses of
Efficacy and Safety, Pediatrics and Neonatology (2016), http://dx.doipatients the PDA was closed after the second course. Among
the responders to the second and third courses, no reopening
was observed. Two patients, in whom the second course
failed, underwent surgical ligation due to ongoing significant
heart failure. The neonatology team carefully evaluated the
patients and could not identify any other reason that could
explain the present congestive heart failure and respiratory
instability. The patients did not have any other known
congenital heart disease. A third course was administered to
the remaining 14 patients, and in five (35%) the PDA closed. In
the remaining nine patients, surgical ligation was performed
(Figure 1). The cumulative closure rate was 71% after the first
course, 83% after the second, and 88% after the third. When
all groups were taken into account, increasing the course
number resulted in a significant increase in the cumulative
closure rate (Cochran’s QZ 25.125, p< 0.001). Comparison
of groups individually showed that the closure rate with a
second course increased significantly (pZ 0.001); however,
there was no significant increase in the closure rate following
the third course (pZ 0.063; Figure 2).
Symptomatic PDA was diagnosed at a mean 97.4 130.7
postnatal hours (range, 24e624 hours). In 76 of 94 infants,
the first course was started during the first four postnatal
days (4/94 during the first 48 hours), and in 72.4% (55/76)
the PDA closed. In 18 infants, the first course was started
after Postnatal Day 4 ( 5 days), and in 66.7% (12/18) the
PDA closed. The difference was not statistically significant
(c2Z 0.231, pZ 0.631).
A comparison of patients who were given single and
multiple courses in terms of clinical features is given in
Table 3. Clinical features other than the need for inotropic
agents were not significantly different between responders
and non-responders to the first course. Need for inotropic
agents was more frequent among patients who needed
multiple courses (pZ 0.007).Oral Ibuprofen in Premature Infants with Patent Ductus Arteriosus:
.org/10.1016/j.pedneo.2015.04.017
Figure 1 A flowchart of the study population. hsPDAZ hemodynamically significant; OIBUZ oral ibuprofen; PDA Z patent
ductus arteriosus.
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+ MODEL3.3. Fluid uptake and urine output
Fluid intake and urine output were evaluated before the
treatment and during each course. Daily fluid intake and
urine output were not significantly different between pa-
tients in whom PDA was closed with single and multiple
courses (Table 3).Mean daily fluid intakewas similar between
responders and non-responders to the first course (Table 3).
3.4. Plasma creatinine level and platelet counts
There were no significant differences in mean urea levels
and median platelet counts before and after each course of
treatment (Table 3).Please cite this article in press as: Olgun H, et al., Repeated Courses of
Efficacy and Safety, Pediatrics and Neonatology (2016), http://dx.doi3.5. Death
A total of 24 patients died (25.5%). The mean GA (27.4 2.4
weeks) and the mean BW (883.5 221.9 g) of the deceased
patients were significantly lower than those of surviving
patients (31.6 2.9 weeks, 1498.0 582.3 g, respectively).
When the GA and BW were added to the model as cova-
riates, binary logistic regression analysis showed that
course number had no significant effect on death
[pZ 0.867, Exp(B)Z 0.901, 95% confidence inter-
valZ 0.264e3.1]. Of 83 patients whose PDAs closed after
single or multiple courses of OIBU, 33.9% died. Of 11 non-
responder patients, 37.5% died. The difference was not
significant (pZ 0.571).Oral Ibuprofen in Premature Infants with Patent Ductus Arteriosus:
.org/10.1016/j.pedneo.2015.04.017
Figure 2 Closure rates after each course of oral ibuprofen.
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There is a significant amount of published data on the ef-
ficacy of single-course OIBU;11e18 however, to the best of
our knowledge, no study in the English literature has re-
ported the results of repeated courses of OIBU. The present
study provides important information about the PDA closure
rates in preterm infants who received single or multiple
courses of OIBU for closure of hsPDA.
After the first course of treatment with OIBU, the PDA
closure rate was reported as between 77% and 100%.10e18 If
the PDA does not close with pharmacological therapy, sur-
gical ligation is the treatment of choice. Use of multiple
courses of IV IBU treatment has been reported since
2009.8,9 Richards et al8 reported a PDA closure rate of 45%
with a single course and of 40.3% with a second course of IV
IBU. They gave a third course to only three patients. They
showed that closure rates were similar with the first and
second IBU treatments in very low birth weight infants, and
they emphasized that second-course treatment could be
considered prior to surgical ligation in very low birth weight
babies in whom the first course had failed. van der Lugt
et al9 reported the closure rates as 66.5% (109/164), 55.8%
(24/43), and 54.5% (6/11) for first, second, and third
courses, respectively, and the difference between the
closure rates was not significant. In our study, the closure
rate was 71% after the first course, 40% after the second
course, and 35% after the third course. Thus, total closure
rates of 71% (67/94) with the first course, 82.9% (78/94)
with the second course, and 90.2% (83/92) with the third
course were achieved. Because of the administration route
and the different BWs and GAs, it is hard to compare our
results to those of Richards et al8 or van der Lugt et al9
Although the cumulative closing rate increased signifi-
cantly (Cochran’s QZ 25.125, p Z< 0.001) with an
increasing course number, a third course did not increase
the closure rate significantly (pZ 0.063: Figure 1). This
result suggests that although a third course of OIBU resultsPlease cite this article in press as: Olgun H, et al., Repeated Courses of
Efficacy and Safety, Pediatrics and Neonatology (2016), http://dx.doiin PDA closure in some additional patients, surgical ligation
may be considered after the second course, especially in
patients with signs of severe heart failure. However, this
suggestion needs to be evaluated by comparing the clinical
outcomes of patients who were operated after two and
three courses of OIBU.
van der Lugt et al9 reported a positive correlation be-
tween the postnatal age at the start of the first dose of IBU
and the need for a second course of IBU. The closure rate in
patients who received a first course in the first 4 postnatal
days was found to be significantly higher.9 However, our
study did not indicate such a relation (Table 3).
The most frequently seen complications of IBU in pre-
mature infants are: thrombocytopenia, oliguria, decrease
in serum sodium level, increase in serum creatinine level,
decrease in urinary sodium excretion, and reductions in
glomerular filtration rate and renal blood flow, together
with an increase in renal vascular resistance, acute renal
failure and feeding intolerance and a potential increase in
the risk for kernicterus.19e27 The reported rates have
differed significantly.10,13,16,17,28,29 van der Lugt et al9
reported oliguria in 10 of 164 infants, thrombocytopenia
in four of 164, and increased serum creatinine level in one
of 164 infants. The complication developed after the
second course in only one infant and during the first course
in the others. In our study, OIBU-related complications
were observed in only three patients (3.2%). As in the
study of van der Lugt et al9, none of the complications
observed in our study was severe, and all resolved after
discontinuation of the drug and were not related to
repeated courses.
Although most of our patients were low birth weight or
very low birth weight preterm infants, the mean GA of our
patients was relatively higher, and this may have affected
our results. For premature infants, many factors may affect
patient outcome. Thus, we could not analyze the effects of
repeated courses of OIBU on the occurrence of the common
problems of preterm infants like retinopathy ofOral Ibuprofen in Premature Infants with Patent Ductus Arteriosus:
.org/10.1016/j.pedneo.2015.04.017
Table 3 Comparison of patients who were given single and multiple courses of oral ibuprofen in terms of clinical features
Variables 1 course (responders) (nZ 67) Multiple courses (non-responders to 1st course) (nZ 27) p
Gestational age (wk) 30.8 3.6 30.1 2.9 c2 0.352
Gestational age groups (wk)
< 30 26 12 2.065 0.356
30e34 28 13
>34 13 2
Postnatal age at 1st course (h) 99.3 143.6 (24e624) 92.7 93.4 0.825
Postnatal age at 1st course (d)
 4 55 21 0.231 0.631
 5 12 6
Birth weight (g) 1398 608 1191 484 0.102
Presence of
Chorioamnionitis 4 3 0.738 0.390
Perinatal asphyxia 10 4 0.000 0.989
Sepsis 36 20 3.307 0.069
Use of antenatal steroids 28 (41.8) 8 (29.6) 0.272
Use of inotropic agents 22 (32.8) 17 (63.0) 0.007
Success rate 67 (71) 16 (59.0) < 0.001
Average fluid intake and urine output
Before the treatment 1st course 2nd course 3rd course
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Day 1 Day 2 Day 3
Fluid intake (mL/kg/d) 164 65 145 60 166 59 196 66 172 57 183 67 182 103 172 83 176 74 183 81 > 0.05
Urine output (mL/kg/h) 3.2 1.1 3.6 1.5 3.7 1.6 4.2 1.6 4.3 1.2 5.3 1.0 3.8 0.7 6.3 0.5 4.1 0.3 4.8 0.3 > 0.05
Closed after 1st course (nZ 67) Remained patent after 1st course (nZ 27)
Fluid intake (ml/kg/dL 98.8 27.9 106.7 25.9 > 0.05
Plasma creatinine level and platelet counts before and after each course of oral ibuprofen
Pretreatment After 1st course After 2nd course After 3rd course
Serum creatinine mg/dL 0.67 0.19 0. 64 0.17 0.69 0.22 0.69 0.21 > 0.05
Platelet count/mL3 (median) 2.2 105 1.9 105 2.0 105 3.3 105 > 0.05
Data are presented as n, n (%), or mean standard deviation, unless otherwise indicated.
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+ MODELprematurity, bronchopulmonary dysplasia, intraventricular
hemorrhage, and NEC.
In conclusion, in preterm babies with hsPDA, repeated
courses of OIBU seem to be effective and safe in PDA
closure. However, the closure rate does not increase
significantly with a third course. Thus, surgical ligation may
be offered after a failed second course, especially in the
case of severe heart failure. New, prospective studies are
needed to evaluate the effects of repeated courses of OIBU
on the prevalence of prematurity problems and the possible
effect of early surgical ligation on the prevention of these
problems with early elimination of ductal shunt.
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